Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 28 Aug 2019 Planned primary completion date changed from 30 Apr 2019 to 3 Jun 2020.
- 04 Dec 2018 New trial record
- 03 Dec 2018 Status changed from not yet recruiting to recruiting.